Exicure to Present Clinical Data at AACR 2020 Virtual Meeting
May 15 2020 - 7:00AM
Business Wire
Poster presentation will show updated
pharmacodynamic and safety data of AST-008 from Exicure’s ongoing
Phase 1b/2 study
Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
constructs, will present at the American Association of Cancer
Research (AACR) Virtual Annual Meeting II, occurring June 22 – 24,
2020.
The AACR poster, by the AST-008 Phase 1b/2 study investigators
and Exicure, titled “Phase 1b/2 Study of an Intratumoral TLR9
Agonist Spherical Nucleic Acid (AST-008) and Pembrolizumab:
Evidence of Immune Activation” will present updated pharmacodynamic
and safety data of AST-008 alone and in combination with
pembrolizumab from Exicure’s ongoing Phase 1b/2 study
(ClinicalTrials.gov identifier: NCT03684785). AST-008 is a novel
SNA configuration of a toll-like receptor 9 (TLR9) agonist
oligonucleotide, designed to trigger anti-tumor immune
responses.
Data to be presented include:
- Gene expression analysis from biopsied tumors, showing trends
to increased lymphocytes in the injected tumor after intratumoral
(IT) AST-008 and in both injected and un-injected tumors after IT
AST-008 plus pembrolizumab combination therapy
- Dose dependent activation of key immune cells and immune system
signal proteins (cytokines/chemokines) after IT AST-008 treatment
and AST-008 plus pembrolizumab treatment
- An emerging safety profile consisting of mostly injection site
reactions and flu-like symptoms, likely reflecting local and
systemic immune activation
- No AST-008-related serious adverse events or dose limiting
toxicity have been reported
This poster will be presented during the AACR Virtual Meeting II
in the session Late-Breaking Research: Clinical Research 1 /
Endocrinology under abstract number LB-140. The poster will be
available for viewing starting on June 22nd.
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company
developing therapeutics for neurology, immuno-oncology,
inflammatory diseases and genetic disorders based on our
proprietary Spherical Nucleic Acid, or SNA technology. Exicure
believes that its proprietary SNA architecture has distinct
chemical and biological properties that may provide advantages over
other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure is in preclinical development of XCUR-FXN, an
SNA–based therapeutic candidate for the treatment of Friedreich’s
ataxia (FA). Exicure's drug candidate AST-008 is currently in a
Phase 1b/2 clinical trial in patients with advanced solid tumors.
Exicure is based outside of Chicago, IL and also has an office in
Cambridge, MA. For more information, visit Exicure’s website at
www.exicuretx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200515005039/en/
Karen Sharma MacDougall 781-235-3060 ksharma@macbiocom.com
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2023 to Jul 2024